Thetis Secures 8.975M To Advance TP-317 Ph 1b In Ulcerative Colitis
09 Jan 2025 //
BUSINESSWIRE
Thetis Pharmaceuticals Appoints Fabio Cataldi to Advisory Roles
14 Nov 2024 //
BUSINESSWIRE
Thetis Pharmaceuticals Reports Positive Phase 1a Results for TP-317
31 Oct 2024 //
BUSINESSWIRE